Literature DB >> 14634101

Vaccination with plasmid DNA activates dendritic cells via Toll-like receptor 9 (TLR9) but functions in TLR9-deficient mice.

Barbara Spies1, Hubertus Hochrein, Martin Vabulas, Katharina Huster, Dirk H Busch, Frank Schmitz, Antje Heit, Hermann Wagner.   

Abstract

We analyzed whether the immunobiology of vaccinating plasmid DNA containing a transcription unit for OVA is influenced by immunostimulatory CpG motifs in the plasmid backbone. Indeed, plasmid DNA differentially activated in vitro myeloid and plasmacytoid dendritic cells (DCs) provided they expressed the CpG-DNA receptor, Toll-like receptor 9 (TLR9). Dependent on the DC subset, activation resulted in type 1 IFN production, while both DC subsets produced IL-6 and up-regulated expression of costimulatory molecules CD40 and CD86. In vivo, however, even upon repeated vaccination with plasmid DNA, priming of OVA-specific CTL and clonal expansion of SIINFEKL-specific CD8 T cells were equal in TLR9-positive and TLR9- or MyD88-negative mice. Overall, these results negate a dominant role of CpG-DNA/TLR9 interactions in long-term vaccination protocols.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14634101     DOI: 10.4049/jimmunol.171.11.5908

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  56 in total

Review 1.  Nucleic acid sensing receptors in systemic lupus erythematosus: development of novel DNA- and/or RNA-like analogues for treating lupus.

Authors:  P Lenert
Journal:  Clin Exp Immunol       Date:  2010-05-07       Impact factor: 4.330

Review 2.  Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination.

Authors:  Christophe J Desmet; Ken J Ishii
Journal:  Nat Rev Immunol       Date:  2012-06-22       Impact factor: 53.106

3.  MyD88 expression is required for efficient cross-presentation of viral antigens from infected cells.

Authors:  Margaret Chen; Christina Barnfield; Tanja I Näslund; Marina N Fleeton; Peter Liljeström
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

Review 4.  Development of TLR9 agonists for cancer therapy.

Authors:  Arthur M Krieg
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

5.  Biomaterials at the interface of nano- and micro-scale vector-cellular interactions in genetic vaccine design.

Authors:  Charles H Jones; Anders P Hakansson; Blaine A Pfeifer
Journal:  J Mater Chem B       Date:  2014-09-12       Impact factor: 6.331

6.  Plasmid vector-linked maturation of natural killer (NK) cells is coupled to antigen-dependent NK cell activation during DNA-based immunization in mice.

Authors:  Ren Zhu; Maryline Mancini-Bourgine; Xiao Ming Zhang; Florence Bayard; Qiang Deng; Marie-Louise Michel
Journal:  J Virol       Date:  2011-07-20       Impact factor: 5.103

7.  Identification of Aim2 as a sensor for DNA vaccines.

Authors:  John J Suschak; Shixia Wang; Katherine A Fitzgerald; Shan Lu
Journal:  J Immunol       Date:  2014-12-08       Impact factor: 5.422

8.  Innate immune recognition of nucleic acids.

Authors:  Tsan Xiao
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829

9.  STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity.

Authors:  Hiroki Ishikawa; Zhe Ma; Glen N Barber
Journal:  Nature       Date:  2009-09-23       Impact factor: 49.962

Review 10.  Novel delivery methods to achieve immunomodulation.

Authors:  David J Gould; Yuti Chernajovsky
Journal:  Curr Opin Pharmacol       Date:  2007-07-03       Impact factor: 5.547

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.